Experienced in Myeloproliferative Neoplasms (MPN)

Rik Schots

Universitair Ziekenhuis Brussel
Brussels, BRU, BE 
Experienced in Myeloproliferative Neoplasms (MPN)
Universitair Ziekenhuis Brussel
Brussels, BRU, BE 
OverviewLocationsClinical Research

Overview

Rik Schots practices in Brussels, Belgium. Mr. Schots is rated as an Experienced expert by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Multiple Myeloma, Kaposi Sarcoma, Philadelphia-Negative Chronic Myeloid Leukemia, Myeloproliferative Neoplasms (MPN), and Bone Marrow Transplant.

His clinical research consists of co-authoring 48 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Myeloproliferative Neoplasms (MPN).

Gender
Male

Locations

Universitair Ziekenhuis Brussel
Brussels, BRU, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2024
Intervention Type: Drug
Study Drugs: CPI-0610 BET Small Molecule Inhibitor, Ruxolitinib
Study Phase: Phase 3
CMV Specific T Cell Therapy for the Treatment of Relapsing or Therapy Refractory CMV Infection After Allogeneic Stem Cell Transplantation With a CMV-positive Donor.
CMV Specific T Cell Therapy for the Treatment of Relapsing or Therapy Refractory CMV Infection After Allogeneic Stem Cell Transplantation With a CMV-positive Donor.
Enrollment Status: Completed
Publish Date: December 21, 2022
Intervention Type: Genetic, Drug
Study Drug: Standard Anti-Viral Therapy
Study Phase: Phase 2
Co-transplantation of Mesenchymal Stem Cells and HLA-mismatched Allogeneic Hematopoietic Cells After Nonmyeloablative Conditioning: a Phase II Randomized Double-blind Study
Co-transplantation of Mesenchymal Stem Cells and HLA-mismatched Allogeneic Hematopoietic Cells After Nonmyeloablative Conditioning: a Phase II Randomized Double-blind Study
Enrollment Status: Terminated
Publish Date: September 08, 2021
Intervention Type: Other, Biological
Study Drug: Mesenchymal Stem Cells
Study Phase: Phase 2
View 2 Less Clinical Trials

48 Total Publications

Blood-derived cell-free DNA is a superior biomarker for noninvasive DNA methylation profiling in multiple myeloma.
Blood-derived cell-free DNA is a superior biomarker for noninvasive DNA methylation profiling in multiple myeloma.
Journal: Blood advances
Published: March 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Schots's expertise for a condition
ConditionClose
      View All 15 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile